Recent results obtained using molecular biology techniques have suggested a possible role for insulin‐like growth factor II (IGF‐II) in the pathogenesis of hepatocellular carcinoma (HCC). To investigate this phenomenon, a monoclonal anti‐body was used against IGF‐II to study 54 patients with HCC. The presence of HBsAg was also tested both in serum and liver tissue. A positive immunoreaction was found in 9/15 (60%) of the HCC arising in cirrhotic livers of patients who had serum markers for HBV (HBV+ positive patients). These results provide further evidence that HBV might play a role in the expression of IGF‐II. In HCC of patients without any markers of HBV infection (HBV‐ negative patients), IGF–II was detected in 10/39 (25.6%) of the tumors, and in some benign neoplastic lesions. It was found not only in neoplastic cells but also in some dysplastic nodules. The speculation arises that IGF–II expression may play a role in some steps of hepato‐carcinogenesis. Copyright © 1994, Wiley Blackwell. All rights reserved
Expression of insulin‐like growth factor II (IGF–II) in human hepatocellular carcinomas: An immunohistochemical study / D'Errico A.; Grigioni W.F.; Fiorentino M.; Baccarinl P.; Lamas E.; Mitri S.D.; Gozzetti G.; Mancini A.M.; Brechot C.. - In: PATHOLOGY INTERNATIONAL. - ISSN 1320-5463. - STAMPA. - 44:2(1994), pp. 131-137. [10.1111/j.1440-1827.1994.tb01697.x]
Expression of insulin‐like growth factor II (IGF–II) in human hepatocellular carcinomas: An immunohistochemical study
D'Errico A.;Grigioni W. F.;Fiorentino M.;Gozzetti G.;Mancini A. M.;
1994
Abstract
Recent results obtained using molecular biology techniques have suggested a possible role for insulin‐like growth factor II (IGF‐II) in the pathogenesis of hepatocellular carcinoma (HCC). To investigate this phenomenon, a monoclonal anti‐body was used against IGF‐II to study 54 patients with HCC. The presence of HBsAg was also tested both in serum and liver tissue. A positive immunoreaction was found in 9/15 (60%) of the HCC arising in cirrhotic livers of patients who had serum markers for HBV (HBV+ positive patients). These results provide further evidence that HBV might play a role in the expression of IGF‐II. In HCC of patients without any markers of HBV infection (HBV‐ negative patients), IGF–II was detected in 10/39 (25.6%) of the tumors, and in some benign neoplastic lesions. It was found not only in neoplastic cells but also in some dysplastic nodules. The speculation arises that IGF–II expression may play a role in some steps of hepato‐carcinogenesis. Copyright © 1994, Wiley Blackwell. All rights reservedI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
